Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9476901 | 0.89 | CTRB1 (0.56) | P2RX7LMNACA2CTRB1CA1 | |
| SCHEMBL7990292 | 0.89 | LMNA (0.48) | P2RX7LMNACA2CTRB1CA1 | |
| SCHEMBL7990303 | 0.85 | P2RX7 (0.47) | P2RX7LMNACA2CTRB1CA5A | |
| SCHEMBL3652008 | 0.84 | P2RX7 (0.51) | P2RX7LMNACA2CA5ACA1 | |
| SCHEMBL3652010 | 0.84 | P2RX7 (0.51) | P2RX7LMNACA2CA5ACA1 | |
| SCHEMBL22552853 | 0.84 | P2RX7 (0.51) | P2RX7LMNACA2CA5ACA1 | |
| SCHEMBL3957822 | 0.84 | P2RX7 (0.54) | P2RX7LMNACTSL | |
| SCHEMBL8539453 | 0.83 | P2RX7 (0.48) | P2RX7LMNACA2CTRB1CA1 | |
| SCHEMBL8539455 | 0.83 | P2RX7 (0.48) | P2RX7LMNACA2CTRB1CA1 | |
| SCHEMBL14370506 | 0.83 | P2RX7 (0.55) | P2RX7CA2CTRB1CA1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | P2RX7 1025/4885LMNA 3190/4885CA2 294/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | P2RX7 1025/4885LMNA 3190/4885CA2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.